• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Patterson, A V
    Williams, Kaye J
    Cowen, Rachel L
    Jaffar, M
    Telfer, Brian A
    Saunders, Mark P
    Airley, R
    Honess, D
    Van der Kogel, A J
    Wolf, C R
    Stratford, Ian J
    Show allShow less
    Affiliation
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
    Issue Date
    2002-07
    
    Metadata
    Show full item record
    Abstract
    Overwhelming clinical and experimental data demonstrate that tumour hypoxia is associated with aggressive disease and poor treatment outcome as hypoxic cells are refractive to radiotherapy and some forms of chemotherapy. However, hypoxia is rare in physiologically normal tissues representing a tumour-specific condition. To selectively target this therapeutically refractive cell population, we have combined bioreductive chemotherapy with hypoxia-directed gene therapy. We have transfected the human fibrosarcoma cell line, HT1080, with a hypoxia-regulated expression vector encoding the human flavoprotein cytochrome c P450 reductase (HRE-P450R). This conferred hypoxia-dependent sensitivity to the alkylating nitroimidazole prodrug RSU1069 in vitro, with a greater than 30-fold increase in oxic/hypoxic cytotoxicity ratio compared with controls. Xenografts of both the HRE-P450R and empty vector transfectants had comparable hypoxic fractions and were refractive to single dose radiotherapy of up to 15 Gy. However, combining a prodrug of RSU1069 with a reduced radiotherapy dose of 10 Gy represents a curative regimen (50% tumour-free survival; day 100) in the HRE-P450R xenografts. In complete contrast, 100% mortality was apparent by day 44 in the empty vector control xenografts treated in the same way. Thus, an oxygen-sensitive gene-directed enzyme prodrug therapy approach may have utility when incorporated into conventional radiotherapy and/or chemotherapy protocols for loco-regional disease in any tissue where hypoxia is a contra-indication to treatment success. doi:10.1038/sj.gt.3301702
    Citation
    Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. 2002, 9 (14):946-54 Gene Ther.
    Journal
    Gene Therapy
    URI
    http://hdl.handle.net/10541/84327
    DOI
    10.1038/sj.gt.3301702
    PubMed ID
    12085243
    Type
    Article
    Language
    en
    ISSN
    0969-7128
    ae974a485f413a2113503eed53cd6c53
    10.1038/sj.gt.3301702
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
    • Authors: Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, Stratford IJ
    • Issue date: 2004 Feb 15
    • A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
    • Authors: McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T, McKeown SR
    • Issue date: 2005 Jul
    • Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
    • Authors: Jounaidi Y, Waxman DJ
    • Issue date: 2000 Jul 15
    • Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
    • Authors: Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, Jaffar M, Stratford IJ, Williams KJ
    • Issue date: 2003 Sep
    • Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.
    • Authors: McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T
    • Issue date: 2003 Jan
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.